SMMT - Summit Therapeutics Inc
IEX Last Trade
13
0.140 1.077%
Share volume: 2,106,166
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$12.86
0.14
1.09%
View ratios
| Fiscal Date | 2022-03-31 | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2022 | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | |
| Report Date | 2022-05-11 | 2022-08-11 | 2022-11-09 | 2023-03-09 | 2023-05-11 | 2023-08-09 | |
| Total revenue | 250.000 K | 235.000 K | 220.000 K | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 250.000 K | 235.000 K | 220.000 K | 0.000 | 0.000 | 0.000 | |
| -6.00% | -6.38% | -100.00% | nan% | nan% | |||
| Operating expenses | 27.215 M | 15.941 M | 22.622 M | 12.964 M | 537.738 M | 15.767 M | |
| Selling general and admin | 6.659 M | 6.933 M | 5.573 M | 7.578 M | 6.940 M | 6.316 M | |
| Research and development | 20.556 M | 9.008 M | 17.049 M | 5.386 M | 530.798 M | 9.451 M | |
| Total expenses | 22.408 M | 12.927 M | 17.160 M | 11.831 M | 537.154 M | 15.794 M | |
| -42.31% | 32.75% | -31.05% | 4,440.22% | -97.06% | |||
| Operating income | -22.158 M | -12.692 M | -16.940 M | -11.831 M | -537.154 M | -15.794 M | |
| Ebit | -22.158 M | -12.692 M | -16.940 M | -11.831 M | -537.154 M | -15.794 M | |
| Pretax income | -21.397 M | -16.771 M | -21.385 M | -19.229 M | -542.376 M | -14.717 M | |
| -21.62% | 27.51% | -10.08% | 2,720.61% | -97.29% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | -21.397 M | -16.771 M | -21.385 M | -19.229 M | -542.376 M | -14.717 M | |
| 21.62% | -27.51% | 10.08% | -2,720.61% | 97.29% | |||
| Net income | -21.397 M | -16.771 M | -21.385 M | -19.229 M | -542.376 M | -14.717 M | |
| 21.62% | -27.51% | 10.08% | -2,720.61% | 97.29% |